



Lung Cancer Video Library

Reach in 2021: 35k+ lung cancer patients

Program Overview:

- Long-running patient education video program featuring top oncologists presenting the most current and emerging treatment options
- Short, 3-5 minute easy-to-understand videos as updates to the searchable online GRACE Lung Cancer Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment



2021 Program Details/Achievements:

The following topics were subjects of video content for the 2021 program year (videos are still in final production/editing at the time of this report)

1. COVID-19-related topics
2. Current Status of Tumor Mutational Burden
3. Immunotherapy for Small Cell Lung Cancer
4. Immunotherapy Combinations for Advanced NSCLC, 2021 Update
5. Immunotherapy before surgery
6. Local therapies for oligometastatic disease
7. Proton Therapy for Locally Advanced NSCLC
8. Emerging Molecular Targets in NSCLC: RET fusions
9. Emerging Molecular Targets in NSCLC: MET
10. Emerging Molecular Targets in NSCLC: KRAS
11. Emerging Molecular Targets in NSCLC: EGFR exon 20 insertions
12. Treatment options for Relapsed SCLC, 2021 Update
13. Translating Molecular Oncology Results into Targeted Therapy Treatment
14. Targeted therapies in early stage lung cancer
15. Utility of Liquid Biopsies, 2021 Update
16. Leading treatment options for patients with negative tumor PD-L1
17. Immunotherapy in patients with driver mutations
18. Identifying an optimal first line therapy for EGFR mutation-positive NSCLC
19. Chemotherapy/EGFR inhibitor combinations in EGFR mutation-positive NSCLC
20. EGFR and angiogenesis inhibitor therapy combinations in EGFR mutation-positive NSCLC

Spanish Language Lung Cancer Video Library

Reach in 2021: 25,000+ lung cancer patients

- Spanish language patient education video program featuring top oncologists
- Short, 3-5 minute easy-to-understand Spanish-language videos as updates to the searchable online GRACE Lung Cancer Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment.



2021 Program Details/Achievements:

11 Videos produced in 2021

1. *Aplicaciones Prácticas de las Biopsias Líquidas en Cáncer de Pulmón y Otros (Practical Application of Liquid Biopsies in Lung and Other Cancers)*
2. *Nuevos Agentes Para las Mutaciones RET, MET, y KRAS (New Agents for RET, MET, and KRAS Mutations)*
3. *DETECCIÓN TEMPRANA EN CÁNCER DE PULMÓN (Early Detection in Lung Cancer)*
4. *ESTADIAJE DEL CÁNCER DE PULMÓN CON EBUS (Lung Cancer Staging with EBUS)*
5. *Terapias Dirigidas para Cáncer Resectado (Targeted Therapies for Resected Cancer)*
6. *Terapias de Primera Línea para Cáncer Avanzado del Pulmón (First Line Therapies for Advanced Lung Cancer)*
7. *INDICACIONES PARA IMMUNOTERAPIA ANTES DE LA CIRCUGÍA (Indications for Immunotherapy before Surgery)*
8. *IMMUNOTERAPIA PARA EL CÁNCER DE PULMÓN LOCALMENTE AVANZADO QUE VIENE DESPUÉS DE PACIFIC (Immunotherapy for Locally Advanced Lung Cancer after PACIFIC)*
9. *UTILIDAD DE TERAPIA DE PROTONES EN CÁNCER (The Usefulness of Proton Therapy in Cancer)*
10. *TERAPIA LOCAL PARA LA ENFERMEDAD OLIGOMETÁTICA (Local Therapy for Oligometastatic Disease)*
11. *DIFERENTES TECNOLOGÍAS DE RADIOTERAPIA EN EL CÁNCER DE PULMÓN EN ESTADIO TEMPRANO (Different Technologies of Radiation Therapy in Early Stage Lung Cancer)*

Mandarin Language Lung Cancer Video Library

Reach in 2021: 100,000+ lung cancer patients between patients in the US and China

- Mandarin language patient education video program featuring top oncologists
- Short, 3-5 minute easy-to-understand Mandarin-language videos with illustrative slides as updates to the searchable online GRACE Lung Cancer Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment



2021 Program Details/Achievements:

The following topics were subjects of video content for the 2021 program year (videos are still in final production/editing at the time of this report):

1. *Current Status of Tumor Mutational Burden*
2. *Immunotherapy for Small Cell Lung Cancer*
3. *Immunotherapy Combinations for Advanced NSCLC, 2020-1 Update*
4. *Proton Therapy for Locally Advanced NSCLC*
5. *Emerging Molecular Targets in NSCLC: RET fusions*
6. *Emerging Molecular Targets in NSCLC: MET*
7. *Emerging Molecular Targets in NSCLC: KRAS*
8. *Emerging Molecular Targets in NSCLC: EGFR exon 20 insertions*
9. *Treatment options for Relapsed SCLC, 2021 Update*
10. *Translating Molecular Oncology Results into Targeted Therapy Treatment*
11. *Utility of Liquid Biopsies*
12. *Leading treatment options for patients with negative tumor PD-L1*
13. *Immunotherapy in patients with driver mutations*
14. *Identifying an optimal first line therapy for EGFR mutation-positive NSCLC*
15. *Chemotherapy/EGFR inhibitor combinations in EGFR mutation-positive NSCLC*
16. *EGFR and angiogenesis inhibitor therapy combinations in EGFR mutation-positive NSCLC*

Targeted Therapies Forum

Reach in 2021 from July 2021 program: 5,000+ views/attendees estimated through 12/31/21 with content available as enduring material for 1 year. Estimating 10,000+ views of content in the first 12 months.

- 1/2 day live virtual event featuring [top oncologists](#) discussing current and emerging information with live audience
- Break out sessions address rare mutations and targeted information
- Interactive program includes live audience and Q&A sessions
- Recorded event is published online as enduring material
- Videos of the recorded event are transcribed so patients may print them and take them to their health care provider appointment



Live virtual event was held on July 17, 2021 virtually due to COVID-19 restrictions and considerations. Hundreds of 'real-time' attendees from around the world viewed the program and had the opportunity to interact with and participate in a live Q&A with the panels. **60 Videos produced for the 2021 program.**

Agenda and topics covered in the 2021 Targeted Therapies Forum:

1. *Tissue Genotyping: Challenges and Best Practices (Optimal NGS Platforms and How to Interpret)*
2. *Liquid Biopsies: Current Applications*
3. *Liquid Biopsies: Future Applications*
4. *Panel Discussion: Acquired Resistance: The Role of Repeat Biopsies (Tissue and Liquid)*
5. *Panel Discussion: Targeted Therapies vs. Immunotherapy*
 - a. *Is There a Role for Single Agent Immunotherapy Ever in Driver Mutation Positive Patients?*
 - b. *Is There a Role for Chemo + IO in Patients with EGFR Mutations and If So, When?*
 - c. *Will There Ever be an Opportunity to use TKI + IO Together?*
6. *The Role of Chemotherapy In Driver Positive Patients*
7. *Genotype Directed Therapies: A Role in Earlier Stage Disease?*
8. *Targeted Therapies in Oligo-Metastatic Disease*
9. *Online Communities: Support, Education and Partnership in Research*
10. *Presentations by Lung Cancer Subtypes:*
 - a. **EGFR GROUP**
 - i. *Current Standards and Novel Therapies for Sensitizing Mutations*
 - ii. *Management of Uncommon EGFR Mutations Including EXON 20*
 - b. **ALK /ROS 1 GROUP**
 - i. *ALK Therapies. Which One Comes First and How Do We Sequence*
 - ii. *ROS Therapies- Current Standard and Emerging Options*
 - c. **KRAS and rare mutations GROUP**
 - i. *KRAS Directed Therapies: A New Horizon*
 - ii. *Rare: NTRK, RET, and HER 2- New Therapies*

Spanish-Language Targeted Therapies Forum

Reach in 2021 from July 2021 program: 5,000+ views/attendees estimated through 12/31/21 with content available as enduring material for 1 year. Estimating 10,000+ views of content in the first 12 months.

- 2.5 hour live event featuring top oncologists from the US, Columbia and Costa Rica discussing current and emerging information with live audience
- Panel discussions address rare mutations and targeted information
- Interactive program includes live audience and Q&A sessions
- Recorded event is published online as enduring material
- Videos of the recorded event are transcribed so patients may print them and take them to their health care provider appointment



Live event was held on July 22, 2021 virtually using Zoom Webinar due to COVID-19 restrictions and considerations. Hundreds of 'real-time' attendees from around the world viewed the program and had the opportunity to interact with and participate in a live Q&A with the panels.

9 videos were produced for the 2021 Spanish-Language Targeted Therapies Forum:

1. *Mutación EGFR: Diferencias en Tratamientos de Primera, Segunda, y Tercera Generación*
2. *Biopsias Líquidas y Tratamiento de Mutaciones en Latinoamérica*
3. *Opciones de Medicamentos en Latinoamérica y Mutaciones Comunes Hispanas*
4. *Mutaciones de EGFR y ROS-1: Inhibidores Orales y Angiogénesis*
5. *Vías RET y NTRK: Tratamiento con Selpercatinib, Pralsetinib, Larotrectinib, y Entrectinib*
6. *KRAS p.G12C y CodeBreak 100, y Krystal-1 y Adagrasib*
7. *Preguntas y Respuestas, Parte 1: Escamosa Versus no Escamosa, BRAF, y Biopsia Líquida*
8. *Preguntas y Respuestas, Parte 2: Resultados de la biopsia, CF/CT DNA, y Telemedicina*
9. *Preguntas y Respuestas, Parte 3: La Importancia de la Orden de Tratamiento y KRAS*

Lung Cancer Roundtable: Direct from ASCO 2021

Reach in 2021: 10k+ lung cancer patients

Program Overview:

- Patient education video program featuring top oncologists discussing the latest current and emerging lung cancer updates direct from ASCO in a roundtable discussion format
- Short, 3-5 minute easy-to-understand videos filmed directly following ASCO
- Videos are transcribed so patients may print them and take them to their health care provider appointment



2021 Program Details/Achievements:

12 Videos produced in 2021

1. *IMpower010: Atezolizumab after Chemo in Non-Small Cell Lung Cancer*
2. *Surgical Outcomes and Checkmate 816: Addition of Nivolumab in Early Stage Non-Small Cell Lung Cancer*
3. *FDA Analysis of Immunotherapy With or Without Chemo in Advanced NSCLC and Low PDL-1*
4. *Poseidon Trial: Durvalumab +/- Tremelimumab vs. Chemo Alone*
5. *Carbo/Pemetrexed/Pembro and Acquired Resistance in EGFRm+ or ALK+ NSCLC*
6. *Immune Therapy for Brain Metastases*
7. *CodeBreak 100: Sotorasib in KRAS G12C Mutation*
8. *Amivantamab and Mobocertinib for EGFR Exon 20*
9. *Amivantamab + Lazertinib in EGFR Mutation, Patritumab Deruxtecan in EGFR Mutation-Positive Acquired Resistance*
10. *MYLUNG Consortium: Overall Biomarker Testing*
11. *Lurbinectedin in Small Cell Lung Cancer and the Failed Atlantis Trial*
12. *Circulatory Tumor DNA*

Case-Based Panel Discussions: Lung Cancer

Reach in 2021: 15k+ lung cancer patients reached

Program Overview:

- Patient education video program featuring a panel of 3-5 leading oncologists presented with lung cancer specific cases highlighting discussion where the video audience is a “fly on the wall” as panelists brainstorm the best approaches to each case in a casual, non lecture setting
- Videos are transcribed so patients may print them and take them to their health care provider appointment



2021 Program Details/Achievements:

The following topics were subjects of video content for the 2021 program year (videos are still in final production/editing at the time of this report):

1. Liquid biopsies
2. New molecular targets
3. Targeted therapy in early stage lung cancer
4. Immunotherapy before surgery
5. Local therapies for oligometastatic disease
6. Unresectable NSCLC management cases
7. Driver Mutations and Biomarker-Driven Therapies in NSCLC - related cases
8. New Frontiers in Immunotherapy - emerging options and the changing landscape in advanced lung cancer
9. SCLC Cases
10. COVID-19-related topics

OncTalk 2021: A Live, Online Patient Education Event

Reach in 2021: 10k+ lung cancer patients reached

Program Overview:

- Live/live streamed program featuring a panel of [top oncologists](#)
- Interactive [program](#) includes live streamed real-time audience; includes a Q&A session
- Recorded event is published online as enduring material
- Videos of the recorded event are transcribed so patients may print them and take them to their health care provider appointment



2021 Program Details/Achievements:

Live event was held on December 11, 2021 virtually using Zoom Webinar due to COVID-19 restrictions and considerations. Hundreds of 'real-time' attendees had the opportunity to interact with and participate in a live Q&A with the panels.

The event was video recorded and segments published as enduring material, resulting in videos produced in 2021 featuring topics of the panel discussions as follows:

1. Early Stage NSCLC
 - a. Molecular Testing
 - i. Testing in potentially resectable NSCLC and unresectable locally advanced NSCLC?
 - ii. Differences by histology and/or smoking status?
 - b. Patient with Resectable NSCLC and EGFR Mutation
 - i. Recommendations depending on stage?
 - c. Anticipated Surgery
 - i. Does the extent of anticipated surgery alter recommendations, specifically the potential need for pneumonectomy?
 - d. Neoadjuvant Therapy vs. Adjuvant Therapy
 - i. Where does it fit in now?
 - ii. Where does it fit in the future?
 - e. The Role of Circulating Tumor DNA for Minimal Residual Disease Today
 - f. Should We Extrapolate Across Molecular Markers in the Curative Setting?
 - g. Should We Incorporate the Rationale From Data in Advanced NSCLC to Early Stage NSCLC?
 - h. What Factors Should Be Considered as We Think About Whether to Adopt a New Intervention Based on a Surrogate Endpoint?
2. Advanced NSCLC
 - a. Is Broad NGS Sequencing the Clear Standard Of Care for Molecular Testing Today?
 - i. Does it apply to squamous NSCLC?
 - ii. What are the leading barriers to seeing this practiced in the community setting?
 - iii. How much can liquid biopsy shore up this gap?
 - iv. How can we improve testing?
 - b. Optimal Timing of KRAS Inhibitor Therapy
 - c. Patient Whose Tumor is Squamous and High Tumor PD-L1

- i. Should we consider foregoing WBRT for brain metastases?*
- d. New Patient Case*
 - i. Squamous NSCLC, PD-L1 60%, >10 small, asymptomatic brain metastases*
- e. Patients with high PD-L1 NSCLC*
 - i. Which should receive chemo with immunotherapy?*
- f. What is the Place of Immunotherapy Doublets vs. Other Options*
- g. Specific Considerations for Patients with Tumor PD-L1 <1%*
- h. Management of Patients With a Driver Mutation Following Acquired Resistance on Targeted Therapy (Once Targeted Therapies are Exhausted)*
 - i. Timing of immunotherapy (if ever)?*
 - ii. Does history of brain metastases matter?*
- i. Use of ctDNA*
 - i. For early assessment of response vs. possible progressing disease?*

GRACECast: A Podcast Series

Reach/Metrics: This program publishes one podcast each week. Listener metrics of 500 for each podcast released and published online for future listening was anticipated within 1 year of each podcast release, totaling over 25,000 'listens' to the 2021 podcast program.



- *Podcast program covering the most current and emerging treatment options which supports the content in the other GRACE programs such as lung cancer, blood cancers, and bladder cancer via an alternate delivery method and additional content*
- *Features leading oncologists in each 5-20 minute episode*
- *One episode will be published per week for 52 weeks designed to help patients by providing an innovative access point*
- *Program supports other GRACE programs by offering access to patient education in an alternative method, allowing patients to watch videos, read articles, and now listen to this educational information while driving, cooking, etc. This will greatly broaden our patient reach.*

2021 Program Details/Achievements:

- *Weekly podcast produced and published all 52 weeks in 2021*
- *Please see full list of podcasts at link above or: <https://cancergrace.org/grace-podcasts>*

COVID-19 Panel Discussions

Reach in 2021: 10k+ cancer patients reached

Program Overview:

- Patient education video program featuring a panel of leading oncologists presenting the most current COVID-19 information it they relates to the cancer journey via short, 3-5 minute easy-to-understand videos
- Panel discussions were produced in both English and Spanish
- Videos are transcribed so patients may print them and take them to their health care provider appointment



2021 Program Details/Achievements:

17 Videos produced in 2021 covering the following topics as panel discussions:

English Language Panel Discussions:

First Session 2022

1. *Trends & Implications - The COVID-19 Pandemic Impact on Cancer Care*
2. *Changes and Challenges of Consistent Cancer Care During the Ongoing Pandemic*
3. *The Continued Use of Telemedicine in Cancer Treatment*
4. *Is the COVID-19 Vaccine Safe For Cancer Patients*
5. *What Patients Should Expect Post COVID-19 Vaccination*
6. *COVID-19 Variants and the Challenge for Cancer Care*

Second Session 2022

1. *The Variable Acceptance of the Covid Vaccine*
2. *The Oncologists Role - Educating Patients During a Pandemic*
3. *Opening Up and Masking - Is it Safe?*
4. *Is There a Place for Telemedicine in Oncology?*
5. *Telemedicine vs. In-Person Intervention - What Have We Learned?*

Spanish Language Panel Discussions:

First Session 2022

1. *Impacto de la Pandemia del Covid-19 en el cuidado de enfermos de cancer (Impact on the COVID-19 Pandemic on Care of Cancer Patients)*
2. *Usos de la Telemedicina para el tratamiento de pacientes con cancer (Use of Telemedicine in the Treatment of Cancer Patients)*
3. *Vacunas contra el COVID en pacientes con cancer (COVID-19 Vaccine in Cancer Patients)*

Second Session 2022

1. *Retrasar el Tratamiento del Cáncer Durante la Pandemia de Covid (Delaying Cancer Treatment During the Covid Pandemic)*
2. *Telemedicina para Pacientes con Cáncer Durante la Pandemia de Covid (Telemedicine for Cancer Patients During the Covid Pandemic)*
3. *La Importancia de la Vacuna Covid para Pacientes con Cáncer (The Importance of the Covid Vaccine for Cancer Patients)*

Melanoma Patient Education Video Library

Reach in 2021: 10k+ melanoma patients reached

Program Overview:

- *Patient Video program featuring leading oncologists providing short, 3-5 minute topic-specific video updates for our searchable online melanoma video library*
- *Videos are transcribed so patients may print them and take them to their health care provider appointment*



2021 Program Details/Achievements:

7 Videos produced in 2021

1. *Potential Toxicities Associated with Immunotherapy in the Treatment of Melanoma*
2. *Treatment Options for Metastatic Melanoma*
3. *The Role of Neoadjuvant Treatment in Melanoma Care*
4. *The Importance of Screening for Skin Cancers*
5. *Molecular Profiling and Driver Mutations in Melanoma Treatment*
6. *Adjuvant Treatment Options for Melanoma*
7. *Leptomeningeal Disease/ Brain Mets in Melanoma*

Head and Neck Cancer Roundtable: Direct from ASCO 2021

Reach: 5k+ head and neck cancer patients reached

Program Overview:

- *Patient education video program featuring top oncologists discussing the latest current and emerging head and neck cancer updates direct from ASCO in a roundtable discussion format*
- *Short, 3-5 minute easy-to-understand videos filmed directly following ASCO*
- *Videos are transcribed so patients may print them and take them to their health care provider appointment*



2021 Program Details/Achievements:

4 Videos produced in 2021:

1. *Curative Modalities and Immunotherapy for Head and Neck Cancers*
2. *HPV and Head and Neck Cancers*
3. *Palliative Care and Studies for Incurable Head and Neck Cancers*
4. *Recent Data and Developments in Palliative Head and Neck Cancer Treatments*

Bladder Cancer Patient Education Video Library

Reach in 2021: 10k+ bladder cancer patients reached

Program Overview:

- Patient Video program featuring leading oncologists providing short, 3-5 minute topic-specific video updates for our searchable online bladder cancer video library
- Videos are transcribed so patients may print them and take them to their health care provider appointment



2021 Program Details/Achievements:

The following topics were subjects of video content for the 2021 program year (videos are still in final production/editing at the time of this report):

1. Immunotherapy in Bladder Cancer
 - a. What is the role of systemic therapy (chemotherapy/ immunotherapy) for neoadjuvant treatment of bladder cancer?
 - b. What is the role of immunotherapy for unresectable bladder cancer?
 - c. What is the role of immunotherapy in cisplatin-ineligible bladder cancer (example, renal dysfunction or neuropathy)? Can it be used first-line?
 - d. What is the role of immunotherapy in frail patients? Can it be used first-line?
 - e. What is the role of immunotherapy in non-muscle invasive bladder cancer?
2. Adjuvant treatment for Bladder Cancer
 - a. What are the indications of administering systemic therapy (chemotherapy/ immunotherapy) post-surgery in bladder cancer?
3. Biomarkers in Bladder Cancer
 - a. Do any biomarkers predict response to immunotherapy in bladder cancer?
 - b. What biomarkers should be performed routinely in bladder cancer?
 - c. What is the role of genetic sequencing of bladder cancer?
4. Role of FGFR testing and inhibitors in advanced bladder cancer
5. COVID-19-related topics

Patient Education Ambassadors Program

Reach in 2021: 15k+ cancer patients reached

Program Overview:

- Fellows and finishing Fellows are recruited to expand and create new content for the GRACE patient education library based on their specialty.
- A portion of this program focuses on communication strategies as they enter their practice.
- Content is created in audio (podcast), written and video formats. Videos are transcribed so patients may print them and take them to their health care provider appointment



GRACE PATIENT EDUCATION
AMBASSADOR PROGRAM
2021-2022

CONGRATULATIONS TO
DR. DANIEL KWON
DR. ERIC SINGHI
DR. AAKASH DESAI
DR. EDINA WANG



2021 Program Details/Achievements:

24 pieces of content to be produced in the 2021 program:

The 2021 program year for the Patient Education Ambassadors program runs from July 1, 2021 - June 30, 2022. Highlights include:

- 2019-2020 program year: 2 Fellows selected and content produced:
 - Dr. Arjun Gupta: Supportive Care (17 videos, 3 articles and 20 podcasts produced)
 - Dr. Narjust Duma: Latino and minority concerns, myths and advocacy (7 videos, 2 articles produced in Spanish)
- 2020-2021 program year: 4 Fellows selected and content produced:
 - Dr. Ana Manana Velazquez: Latino and minority concerns and advocacy regarding COVID-19 with Dr. Idalid Franco as well as content about radiation oncology (6 videos produced in Spanish)
 - Dr. Abdul Rafeh Naqash: Clinical trials education and minority reach (12 videos produced)
 - Dr. Idalid Franco: Latino and minority concerns and advocacy regarding COVID-19 with Dr. Ana Manana Velazquez as well as content about radiation oncology (6 videos produced in Spanish)
 - Dr. Medhavi Gupta: Healthcare disparities; breast cancer (15 videos produced)
- 2021-2022 program year: 4 Fellows selected: Content to be produced in early 2022
 - Dr. Aakash Desai: health disparities and infographics for patients in India and Nepal
 - Dr. Daniel Kwon: Prostate cancer and decision aids
 - Dr. Edina Wang: Chinese health literacy and radiation oncology
 - Dr. Eric Singhi: Misinformation mitigation and reaching medically underserved

Online Forum Monthly Sponsorship

Reach/Metrics: The GRACE website receives over 1,000,000 visitors each year, and the Online Forum is one of the main features of our website. Our Online Forum receives thousands of new topic threads each year, creating a hub of information on our website.

Get help, ask a question,
share experiences and
information

Ask a Question



Sponsor Spotlight Sponsorship

Reach/Metrics: The semi-monthly GRACE newsletter, GRACENotes reaches over 1,000,000 patients each year through direct distribution and online publishing. The newsletter features new program information as well as links to threads on our Online Forum, creating a valuable, concise resource for patients to drill down to educational content and stay abreast of new content we are publishing throughout the year.

GRACE Global Reach by Country 2021

Afghanistan	4
Albania	14
Algeria	23
Andorra	2
Angola	7
Antigua & Barbuda	2
Argentina	81
Armenia	6
Aruba	6
Australia	3,709
Austria	109
Azerbaijan	6
Bahamas	16
Bahrain	6
Bangladesh	163
Barbados	7
Belarus	15
Belgium	191
Belize	21
Bermuda	18
Bolivia	10
Bosnia & Herzegovina	43
Botswana	4
Brazil	245
British Virgin Islands	1
Brunei	7
Bulgaria	77
Cambodia	15
Cameroon	7
Canada	6,053

Cape Verde	1
Caribbean Netherlands	3
Cayman Islands	1
Chile	35
China	108,624
Colombia	70
Congo - Kinshasa	5
Costa Rica	10
Côte d'Ivoire	2
Croatia	142
Cuba	4
Cyprus	14
Czechia	57
Denmark	104
Djibouti	1
Dominica	2
Dominican Republic	7
Ecuador	14
Egypt	11
Egypt	180
El Salvador	13
Equatorial Guinea	1
Estonia	11
Eswatini	1
Ethiopia	14
Fiji	3
Finland	97
France	378
Gambia	1
Georgia	18
Germany	1,456
Ghana	19
Gibraltar	2
Greece	169

Greenland	1
Grenada	1
Guam	4
Guatemala	11
Guernsey	11
Guyana	1
Haiti	2
Honduras	8
Hong Kong	330
Hungary	73
Iceland	19
India	17,218
Indonesia	282
Iran	74
Iraq	45
Ireland	650
Israel	133
Italy	326
Jamaica	17
Japan	247
Jersey	6
Jordan	45
Kazakhstan	18
Kenya	53
Kosovo	30
Kuwait	23
Kyrgyzstan	2
Laos	4
Latvia	20
Lebanon	56
Liberia	2
Libya	9
Lithuania	24
Luxembourg	20

Macao	4
Malawi	1
Malaysia	346
Maldives	1
Mali	1
Malta	24
Martinique	1
Mauritania	1
Mauritius	15
Mexico	180
Moldova	8
Mongolia	4
Montenegro	10
Morocco	29
Mozambique	7
Myanmar (Burma)	15
Namibia	9
Nepal	32
Netherlands	959
New Zealand	287
Nicaragua	3
Niger	3
Nigeria	188
North Macedonia	221
Norway	99
Oman	23
Pakistan	248
Palestine	7
Panama	10
Papua New Guinea	2
Paraguay	6
Peru	71
Philippines	1,731
Poland	150

Portugal	79
Puerto Rico	50
Qatar	24
Réunion	2
Romania	162
Russia	179
Rwanda	4
San Marino	1
São Tomé & Príncipe	1
Saudi Arabia	169
Senegal	2
Serbia	98
Seychelles	1
Singapore	512
Saint Maarten	1
Slovakia	31
Slovenia	69
Somalia	4
South Africa	311
South Korea	287
South Sudan	1
Spain	501
Sri Lanka	79
St. Lucia	2
St. Pierre & Miquelon	1
St. Vincent & Grenadines	1
Sudan	13
Suriname	1
Sweden	204
Switzerland	1,095
Syria	9
Taiwan	213
Tanzania	11
Thailand	248

Togo	1
Trinidad & Tobago	21
Tunisia	13
Turkey	243
Turkmenistan	1
Turks & Caicos Islands	1
U.S. Virgin Islands	1
Uganda	42
Ukraine	222
United Arab Emirates	169
United Kingdom	16,153
Uruguay	8
Uzbekistan	12
Venezuela	19
Vietnam	154
Yemen	4
Zambia	6
Zimbabwe	14

Total reach outside the United States	168,249
--	----------------